Search

According to the World Health Organization, oncological diseases are a common cause of mortality in the population, as a result of which the development of measures aimed at the prevention of carcinogenesis is urgent. This study is devoted to obtaining a probiotic consortium consisting of bacteria isolated from the gastrointestinal tract of a healthy person, with the further prospect of its use in anticancer therapy in the form of a biologically active additive (BAA) in specialized food products. The object of the study was bacteria isolated from the feces of a healthy person, and consortia based on them. The identification of bacteria and the study of antimicrobial, antioxidant activity, antitumor properties, resistance to antibiotics, acidic medium and bile of bacteria and consortia based on them were carried out according to generally accepted methods. The results of the study are the formation of consortia of isolated and identified bacteria: № 1 – B. bifidum, B. breve, L. plantarum, L. acidophilus, № 2 – B. bifidum, B. breve, L. plantarum, L. fermentum, № 3 – B. breve, L. fermentum, S. salivarius, № 4 – B. breve, L. fermentum, S. thermophiles exhibiting probiotic properties. Consortium № 2 showed antimicrobial activity to the largest number of test cultures; moderate resistance to the largest number of antibiotics – № 1 and № 2; the highest antioxidant activity – № 1, the most pronounced anti-cancer properties in relation to HepG2, LBR2, MDA-MB-231, U87 and Panc-1 – № 4, and to MCF-7 – № 3; the greatest resistance to environments with low acidity and bile – № 2. According to the results of the study, it can be said that the isolated strains, like the consortia based on them, had antimicrobial, antioxidant activity, showed an antitumor effect, resistance to antibiotics, bile and an acidic environment, so that they can be used as probiotic agents in the form of dietary supplements and specialized lactic acid products for the prevention of carcinogenesis.